Two Phase 3 Trials of Dupilumab versus Placebo in Atopic …
WEBOct 1, 2016 · In two phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved the signs and symptoms of atopic dermatitis, including pruritus, symptoms of anxiety and...
Press Release: Dupixent phase 3 study confirms significant
WEBSep 11, 2005 · A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines.
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant
WEBSep 11, 2024 · The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEB2 days ago · Following recentapprovals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life compared to placebo.
Second positive Phase 3 trial for Dupixent® | Sanofi
WEBNov 27, 2006 · The second Dupixent ® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
Second positive Phase 3 Dupixent® (dupilumab) trial confirms
WEBJan 19, 2006 · Dupixent is the first and only medicine to demonstrate positive Phase 3 results in prurigo nodularis, confirming the potential benefit of targeting IL-4 and IL-13, central drivers of type 2 inflammation, to address itch and skin lesions.
Dupixent® late-breaking data from NOTUS confirmatory phase 3 …
WEBMay 20, 2024 · NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation.
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results …
WEBMay 21, 2023 · Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine. Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo.
A Review of Phase 3 Trials of Dupilumab for the Treatment of …
WEBAug 26, 2022 · Phase 3 clinical trials demonstrate that treatment with dupilumab for moderate-to-severe AD results in rapid and sustained improvements in AD signs and symptoms and is generally well tolerated across age groups.
Press Release: Dupixent® (dupilumab) Phase 3 Results show
WEBOct 22, 2023 · The Phase 3, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of Dupixent in children aged 1 to 11 years with EoE, as determined by histological,...
- Some results have been removed